High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules

Vaccine

Volumn 18, Issue 25, 2000, Pages 2843-2855

  Benmohamed, Lbachir ^a   Thomas, Alan ^b   Bossus, Marc ^c   Brahimi, Karima ^a   Wubben, Jacqueline ^b   Gras Masse, Hélène ^c   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Immunogenicity; Lipopeptides; Plasmodium falciparum

Indexed keywords

GAMMA INTERFERON; LIPOPEPTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; ERYTHROCYTE LIFESPAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; NONHUMAN; PEPTIDE SYNTHESIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPOROZOITE; VACCINATION;

EID: 0034659607     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00068-2     Document Type: Article

References (61)

1. Marsh K. Malaria disaster in Africa. Lancet. 352:1998;924.
2. Trape J.-F., et al. Impact of chloroquine resistance on malaria mortality. C.R. Acad. Sci. Paris. 321:1998;689-697.
3. Clyde D.F. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull. WHO. 68:(Suppl.):1990;9-12.
4. Mellouk S., Lunel F., Sedegah M., Beaudoin R.L., Druilhe P. Protection against malaria induced by irradiated sporozoites. Lancet. 335:(8691):1990;721.
5. Druilhe P., Marchand C. From sporozoite to liver stages: the saga of the irradiated sporozoite vaccine. McAdam K. New strategies in parasitology. 1989;39-48 Churchill Livingstone, Edinburgh.
6. Druilhe P., Renia L., Fidock D.F. Immunity to the liver stages. Sherman I. Malaria. 1998;513-543 ASM Press, Washington, DC.
7. Rénia L., Rodrigues M.M., Nussenzweig V. Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage. Immunology. 82:1994;164-168.
8. Scheller L.F., Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. USA. 92:1995;4066-4068.
9. Guerin-Marchand C., et al. A liver stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature. 329:1987;164-167.
10. Marchand C., Druilhe P. How to select Plasmodium falciparum pre-erythrocytic antigens in an expression library without defined probe. Bull. WHO. 68:(Suppl.):1990;158-164.
11. Fidock D.A., et al. Plasmodium falciparum liver stage-specific antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 153:1994;190-204.
12. Fidock D.A., et al. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP. Molec. Biochem. Parasitol. 64:1994;219-232.
13. Pasquetto P., et al. Plasmodium falciparum sporozoite invasion is inhibited by naturally-acquired or experimentally-induced polyclonal antibodies to the STARP antigen. Eur. J. Immunol. 27:1997;2502-2513.
14. Bottius E., et al. A Novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. J. Immunol. 156:1996;2874-2884.
15. Benmohamed L., et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1997;1242-1253.
16. Perlaza B.L., et al. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect. Immun. 66:(7):1998;3423-3428.
17. Thomas A.W., Slierendregt B., Mons B., Druilhe P. Chimpanzees and supporting models in the study of malaria pre-erythrocytic stages. Mem. Inst. Oswaldo Cruz. 89:1994;111-114.
18. Haynes B.F., Dowell B.L., Hensley L.L., Gore I., Metzgar R.S. Human T cell antigen expression by primate T cells. Science. 215:1982;298-300.
19. Geluk A., et al. Evolutionary conservation of major histocompatibility complex-DR/Peptide/T cell interactions in primates. J. Exp. Med. 177:1993;979-991.
20. Meis J.F.G.M., et al. Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp. Parasitol. 70:1990;1-11.
21. Martinon F., et al. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:(10):1992;3416-3422.
22. Bourgault I., et al. Simian immunodeficiency virus as a model for vaccination against HIV: induction in rhesus macaques of GAG- and NEF specific cytotoxic T lymphocytes by lipopeptides. J. Immunol. 152:1994;253-261.
23. Déprez B., et al. Pimelautide or Trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response. J. Med. Chem. 38:1995;459-465.
24. Turner J.L., Trauger R.J., Daigle A.E., Carlo D.J. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS. 8:1994;1429-1435.
25. Déprez B, Sauzet JP, Boutillon C, Martinon F, Tartar A, Sergheraert C, Guillet JG, Gomard E, Gras-Masse H, Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTLO 14, Vaccine 1996;14,375-82.
26. Estaquier J., et al. The Mixotope: a combinatorial peptide library as a T cell and B cell immunogen. Eur. J. Immunol. 24:1994;2789-2795.
27. Good M.F., et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science. 235:1987;1059-1062.
28. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 84:(5):1994;1594-1602.
29. Troye-Blomberg M., et al. T and B cell responses of Plasmodium falciparum malaria-immune individuals to synthetic peptides corresponding to sequences in different regions of the P. falciparum antigen Pf155/RESA. J. Immunol. 143:(9):1989;3043-3408.
30. Brahimi K., et al. Fast immunopurification of small amounts of specific antibodies on peptides bound to ELISA plates. J. Immunol. Methods. 162:1993;69-75.
31. Druilhe P., Miltgen F., Boulard Y., Landau I. Exo-erythrocytic schizogony of Plasmodium falciparum in monkey Cebus apella. Molec. Bioch. Parasit. 108:(Suppl.):1982;125-133.
32. Kabilan L., et al. T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc. Natl. Acad. Sci. USA. 85:1988;5659-5663.
33. Auriault C., et al. Epitopic characterization and vaccinal potential of peptides derived from a major antigen of Schistosoma mansoni (Sm28 GST). Pept. Res. 4:(1):1991;6-11.
34. Estaquier J., et al. Determination of B-cell epitopes of nef HIV-1 protein: immunogenicity related to their structure. Molec. Immunol. 29:(11):1992;1337-1345.
35. Higgins J.A., Thorpe C.J., Hayball J.D., O'Hehir R.E., Lamb J.R. Overlapping T-cell epitopes in the group I allergen of Dermatophagoides species restricted by HLA-DP and HLA-DR class II molecules. J. Allergy. Clin. Immunol. 93:1994;891-899.
36. Meister G.E., Roberts C.G.P., Berzofsky J.A., De Groot A.S. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine. 13:1995;581-591.
37. Landry S.J. Local protein instability predective of helper T-cell epitopes. Immunol. Today. 18:1997;527-532.
38. Good M.F., Kumar S., Miller L.H. The real difficulties for malaria sporozoite vaccine development: non responsiveness and antigenic variation. Immunol. Today. 9:(11):1988;351-355.
39. Etlinger H.M., et al. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J. Immunol. 140:(2):1988;626-633.
40. Nardin E.H., Barr P.J., Heimer E. Etlinger H.M. Genetic restriction of the murine humoral response to a recombinant Plasmodium vivax circumsporozoite protein. Eur. J. Immunol. 18:1988;1119-1122.
41. Udhayakumar V., et al. Antigenic diversity in the circumsporozoite protein of Plasmodium falciparum abrogates cytotoxic-T-cell recognition. Infect. Immun. 62:(4):1994;1410-1413.
42. Ballou W.R., Rothbad J., Wirtz R.A., Gordon D.M., Williams J.S., Gore R.F., Schneider I., Hollingdale M.R., Beaudoin R.L., Malloy W.L., Miller L.H., Hockmeyer W.T. Immunogenicity of synthetic peptides from the circumsporozoite protein of Plasmodium falciparum. Science. 228:1985;996-999.
43. Ballou W.R., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Lancet. 1:1987;1277-1281.
44. Fries L.F., et al. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsprozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect. Immun. 60:(5):1992;1834-1839.
45. Herrington D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:1987;257.
46. Heppner D.G., et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174:1996;361-366.
47. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England Journal of Medicine. 336:1997;86-91.
48. Gupta R.K., Siber G.R. Adjuvants for human vaccines-current status problems and future prospects. Vaccine. 13:1995;1263-1276.
49. Amador R., et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 166:1992;139-144.
50. Noya O.Y., Berti de G. Alarcon Noya B. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170:1994;396.
51. Deres K., Schild H., Karl-Heinz W., Jung G., Rammenensee H.-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564.
52. Wiesmüller K.H., et al. The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant. Immunology. 72:1991;109.
53. Roggero M.A., et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol. Immunol. 32:1995;1301-1309.
54. Sturchler D., et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am. J. Trop. Med. Hyg. 53:1995;423-431.
55. Etlinger H.M., et al. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect. Immun. 59:1991;3498-3503.
56. Surcel H., et al. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology. 81:1994;171-176.
57. De Kroon A.I.P.M., McConnell H.M. Enhancement of peptide antigen presentation by a second peptide. Proc. Natl. Acad. Sci. 90:1993;8797-8801.
58. Redhead K., et al. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity. Biologicals. 22:1994;339-345.
59. Mellouk S., et al. Inhibitory effect of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J. Immunol. 139:1987;4192-4195.
60. Friede M., et al. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes. Vaccine. 9:1994;791-797.
61. Hoffman S.L., Franke E.D., Hollingdale R., Druilhe P. Attacking the infected hepatocyte. Hoffman S.L. Malaria vaccine development. 1996;40 ASM publications, Washington.